Core Insights - The launch meeting for the Phase III clinical trial of ACC017, a new integrase inhibitor developed by Aidi Pharmaceutical Group, was held in Yangzhou, Jiangsu, with participation from key researchers and clinical units [1][3] - Aidi Pharmaceutical focuses on meeting clinical needs in the HIV field, emphasizing innovation and development of anti-HIV drugs [1][3] Group 1: Clinical Development - Dr. Fu Helian presented the research pipeline for Aidi's anti-HIV drugs, highlighting the clinical value and potential of ACC017 in terms of antiviral efficacy, safety, and resistance profile [3] - The project team introduced the Phase III clinical trial protocol and project plan, with experts discussing details and considerations for the trial's execution [4] Group 2: Market Position and Collaboration - Professor Zhang Fujie discussed international clinical research progress in HIV prevention and treatment, noting the high antiviral efficacy and clinical value of the domestic anti-HIV drug Ainomi [3] - Experts expressed confidence in the breakthrough of domestic integrase inhibitors and the importance of collaboration with clinical centers to advance the trial and contribute to innovative drug development in China [4]